Jump to content

New clinical trial

David A

Recommended Posts

I recieved this email from somewhere on the net I'm not advertising for anyone just passing along hopefully usefull info for someone. David A

Lung Cancer Clinical Trial

At some point in the past you used the NexProfiler Treatment Option Tool for Lung Cancer. At the time you registered for this treatment decision tool, you indicated that you would be interested in being contacted by NexCura, which operates the NexProfiler Tool for Cancer, for opportunities to participate in clinical research specific to the treatment of lung cancer.

I am writing to let you know that a Phase 3 clinical trial for non small-cell lung cancer is currently enrolling at clinical sites throughout the United States. The trial, known as the ASSIST-2 trial, is studying an investigational cancer drug called TLK286 (or Telcyta™). TLK286 was discovered and is being developed by Telik, Inc.

Telik has created a Web site — www.ASSIST-2Trial.com — to provide detailed information about the ASSIST-2 clinical trial and TLK286.

In order to be eligible to be considered for enrollment in the ASSIST-2 trial, you must meet all these criteria:

You must be 18 years of age or older.

You must be diagnosed with non small-cell lung cancer.

You must have recurrent non-small cell lung cancer that can be measured with a CT scan, MRI scan or physical exam.

You must have received two prior chemotherapy regimens.

The two chemotherapy regimens must have included a platinum agent and docetaxel.

You have never received TLK286 or Iressa®.

If you are interested in learning more about this study, please visit — www.ASSIST-2Trial.com

If you have any questions or concerns about this e-mail, please contact:

E-mail: info@education.nexcura.com

Address: Patient Information Services,

1725 Westlake Avenue North, Suite 300, Seattle WA 98109

If you wish to review NexCura's Privacy Statement, visit: http://www.NexCura.com/nexcura/Nexcura_Privacy.asp

You have received this e-mail as a result of your request for information when you registered with NexCura, Inc. You may unsubscribe from this e-mail notification service at any time by going to the following page: http://www.nexcura.com/EU.asp?ESubId=38 ... 3%24%27%23

NexCura will not release your e-mail address or other personally identifying information.

Iressa (gefitinib) is a registered trademark of the AstraZeneca group of companies.


Contact Us

Privacy Policy

Learn More

About the ASSIST-2 Trial

Click Here.

The NexCura logo is a registered trademark of NexCura, Inc. Copyright © 2004 NexCura, Inc. All rights reserved

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.